Metraipolis › archive › dc_00317f05e899
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized… — Europe PMC PMID:41609753
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41609753
- DOI
- 10.1001/jamaoncol.2025.6245
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T11:18:02.563Z
- SHA-256 of the archived text
1d2bc1f6f7b015a65af82341f7a74b9511fc9ed27c6f938e6f1816f9a866590c- Stable URL of this page
https://metraipolis.com/documento/dc_00317f05e899
How to cite
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized… — Europe PMC PMID:41609753 — Europe PMC (en), https://europepmc.org/article/MED/41609753 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_00317f05e899 (Metraipolis archive dc_00317f05e899, sha256 1d2bc1f6f7b015a65af82341f7a74b9511fc9ed27c6f938e6f1816f9a866590c)
BibTeX
@misc{dc00317f05e899,
title = {Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized… — Europe PMC PMID:41609753},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41609753},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_00317f05e899; sha256 1d2bc1f6f7b015a65af82341f7a74b9511fc9ed27c6f938e6f1816f9a866590c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41609753. Agents can read the archived copy with the MCP tool read_document.